Literature DB >> 605744

Dopaminergic stimulation of HGH in diabetes mellitus and in obesity.

G Gragnoli, V Palazzuoli, R Favilli, I Tanganelli, G Migliarese.   

Abstract

The behavior of HGH in basal conditions and after L-Dopa infusion was studied in a group of patients with diabetic retinopathy, in 9 obese and 8 control subjects. In both diabetics and obese subjects, increases found in HGH plasma levels after administration of the drug were slighter than in the controls. On the basis of these results it can be concluded that in diabetics the availability of energetic substrates may modify the HGH response to the L-Dopa stimulus. In obesity, the possibility is considered of a reversible response to the L-Dopa stimulus. In obesity, the possibility is considered of a reversible defect in the sensitivity of the dopaminergic receptors, induced by metabolic and endocrine factors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 605744     DOI: 10.1007/bf02581401

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  19 in total

Review 1.  Neuropharmacologic control of neuroendocrine function in man.

Authors:  L A Frohman; M E Stachura
Journal:  Metabolism       Date:  1975-02       Impact factor: 8.694

2.  Abnormal serum growth hormone response to exercise in maturity-onset diabetics.

Authors:  A P Hansen
Journal:  Diabetes       Date:  1973-08       Impact factor: 9.461

3.  Prevention of L-dopa-induced growth hormone stimulation by hyperglycemia.

Authors:  R B Mims; C L Scott; O M Modebe; J E Bethune
Journal:  J Clin Endocrinol Metab       Date:  1973-11       Impact factor: 5.958

4.  Plasma growth hormone response to L-dopa in obese subjects.

Authors:  M Fingerhut; D T Krieger
Journal:  Metabolism       Date:  1974-03       Impact factor: 8.694

5.  The effect of weight loss on the growth hormone response to arginine infusion in obesity.

Authors:  A Z el-Khodary; M F Ball; B Stein; J J Canary
Journal:  J Clin Endocrinol Metab       Date:  1971-01       Impact factor: 5.958

6.  Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients.

Authors:  F Cavagnini; M Peracchi; G Scotti; U Raggi; A E Pontiroli; R Bana
Journal:  J Endocrinol       Date:  1972-09       Impact factor: 4.286

7.  Radioimmunoassay of human growth hormone.

Authors:  G M Molinatti; F Massara; E Strumia; F Pennisi; G A Scassellati; L Vancheri
Journal:  J Nucl Biol Med       Date:  1969 Jan-Jun

8.  Stimulation of human-growth-hormone secretion by L-dopa.

Authors:  A E Boyd; H E Lebovitz; J B Pfeiffer
Journal:  N Engl J Med       Date:  1970-12-24       Impact factor: 91.245

9.  Plasma insulin and growth hormone levels in obesity and diabetes.

Authors:  R S Yalow; S M Glick; J Roth; S A Berson
Journal:  Ann N Y Acad Sci       Date:  1965-10-08       Impact factor: 5.691

10.  Diabetes, diabetic angiopathy, and growth hormone.

Authors:  K Lundbaek; N J Christensen; V A Jensen; K Johansen; T S Olsen; A P Hansen; H Orskov; R Osterby
Journal:  Lancet       Date:  1970-07-18       Impact factor: 79.321

View more
  2 in total

1.  Study of pituitary secretion in relation to retinopathy in patients with juvenile diabetes mellitus.

Authors:  G A Cerasola; M Donatelli; D Sinagra; V Russo; L M Amico; G Lodato
Journal:  Acta Diabetol Lat       Date:  1981 Oct-Dec

Review 2.  The Human Experience with Intravenous Levodopa.

Authors:  Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal:  Front Pharmacol       Date:  2016-01-06       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.